Seattle-Lausanne-Kampala CTU

描述(由申请人提供)：西雅图-洛桑-坎帕拉临床试验单位(SLK CTU)在未来七年有一个共同的目标，那就是努力建设一个没有艾滋病的世界。拟议的CTU由弗雷德·哈钦森癌症研究中心(FHCRC)管理，将整合现有的三个高性能CTU，并在撒哈拉以南非洲增加一个经验丰富的高容量CRS。SLK CTU将利用六位国际艾滋病毒-1领导人的集体不同专业知识，他们在过去2-30年里为改进艾滋病毒-1疫苗的开发、预防和护理做出了重大贡献。四个综合临床研究站点(CRSS)将针对NIAID HIV网络的四个领导议程：西雅图VMP(疫苗、杀微生物剂和预防)、西雅图的UW ACTU(成人治疗)、洛桑VIC(沃多伊斯大学中心医院)(疫苗)和坎帕拉的卡桑加蒂传染病研究所(IDI)(预防和成人治疗)。为了实现CTU的共同目标和网络的议程，临床研究和活动将针对以下四个具体目标： 具体目标1：发挥领导作用和专业知识，处理与艾滋病毒-1疫苗接种、预防、杀微生物剂和疗法有关的当前和新的科学优先事项。 具体目标2：通过整合我们现有CTU和临床试验计划的现有基础设施和运营，提供集中的行政监督，以整合和扩大四个网络内的CRS活动。 具体目标3：在NIAID赞助的四个艾滋病毒网络的指导下进行第1-3阶段临床试验，并提供必要的试验支助，以确保临床研究的最高质量标准。 具体目标4：继续和扩大与CRS社区和利益攸关方的伙伴关系，争取他们的支持，并保证受艾滋病毒流行影响的相关研究人群成功登记和参与。 我们的反恐联盟认识到前进的挑战。我们的结构、专业知识和在丰富环境中利用相关活动的能力的固有特征为TE临床试验网络提供了创新。

DESCRIPTION (provided by applicant): The Seattle-Lausanne-Kampala Clinical Trials Unit (SLK CTU) shares a common goal over the next seven years to work toward a world free of AIDS. The proposed CTU, administered through Fred Hutchinson Cancer Research Center (FHCRC), will consolidate three current high-performing CTUs and add one new experienced, high-capacity CRS in sub-Saharan Africa. The SLK CTU will harness the collective diverse expertise of six international HIV-1 leaders who have made significant contributions to improve HIV-1 vaccine development, prevention and care over the past 2-3 decades. The four integrated Clinical Research Sites (CRSs) will address four NIAID HIV network leadership agendas: Seattle VMP (vaccine, microbicide, and prevention), UW ACTU in Seattle (adult therapeutic), Lausanne VIC (Centre Hospitaller Universitaire Vaudois) (vaccine), and Kasangati-lnfectious Diseases Institute (IDI) in Kampala (prevention and adult therapeutic). To accomplish the CTU's common goal and the networks' agendas, clinical research studies and activities will be directed toward the following four specific aims: Specific Aim 1: Contribute leadership and expertise to address current and new scientific priorities related to HIV-1 vaccination, prevention, microbicides and therapeutics. Specific Aim 2: Provide centralized administrative oversight through consolidation of the current infrastructure and operations of our existing CTUs and clinical trials programs, to integrate and expand the CRS activities within the four networks. Specific Aim 3: Conduct phase 1-3 clinical trials under the direction of the four NIAID- sponsored HIV networks and provide the trial support necessary to ensure the highest quality standards of clinical research. Specific Aim 4: Continue and extend partnerships with the CRS communities and stakeholders to enlist their support and guarantee successful enrollment and participation of relevant study populations that are impacted by the HIV epidemic. Our CTU recognizes the challenges moving forward. Inherent characteristics of our structure, expertise, and ability to leverage related activities in our rich environment offer innovation to te clinical trials networks.